IgD κ multiple myeloma and myelodysplastic syndrome

Blood. 2017 Apr 13;129(15):2203. doi: 10.1182/blood-2016-09-738120.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Abnormal Karyotype
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Bortezomib / administration & dosage
  • Dexamethasone / administration & dosage
  • Erythroblasts / metabolism
  • Erythroblasts / pathology
  • Erythropoietin / administration & dosage
  • Female
  • Humans
  • Immunoglobulin D / blood*
  • Immunoglobulin D / genetics
  • Melphalan / administration & dosage
  • Multiple Myeloma* / blood
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics
  • Multiple Myeloma* / pathology
  • Myelodysplastic Syndromes* / blood
  • Myelodysplastic Syndromes* / diet therapy
  • Myelodysplastic Syndromes* / genetics
  • Myelodysplastic Syndromes* / pathology
  • Neutrophils / metabolism
  • Neutrophils / pathology
  • Proto-Oncogene Proteins c-myc / genetics
  • Proto-Oncogene Proteins c-myc / metabolism

Substances

  • EPO protein, human
  • Immunoglobulin D
  • MYC protein, human
  • Proto-Oncogene Proteins c-myc
  • Erythropoietin
  • Bortezomib
  • Dexamethasone
  • Melphalan